Both in Pharmaceuticals
Zenas BioPharma vs SELLAS Life Sciences Group
Over the past year ZBIO returned −7.9% and SLS returned +393.4%; their daily moves had a correlation of 0.10.
ZBIO −7.9% SLS +393.4%Growth of $1, one year, split-adjusted
| Metric | ZBIO | SLS |
|---|---|---|
| Price | $28.87 | $8.83 |
| Market cap | $1.88B | $1.78B |
| Today | +4.53% | +3.29% |
| 1 month | +3.7% | −24.1% |
| 6 months | +39.1% | +81.3% |
| Year to date | −20.5% | +134.2% |
| 1 year | −7.6% | +385.2% |
| Revenue growth (YoY) | — | — |
| Gross margin | 100.0% | — |
| Net margin | −11145.6% | — |
| P/E (TTM) | — | — |
| Price / sales | 1,881.7× | — |
| Net cash | $346.1M | $138.3M |
| Dividend yield | — | — |
| Volatility (60d) | 56.4% | 96.7% |
| Short % of float | 40.2% | 27.0% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).